Published in J Neuroinflammation on June 20, 2005
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation (2008) 2.03
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation (2007) 1.70
Inflammasomes in the CNS. Nat Rev Neurosci (2014) 1.44
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J (2009) 1.39
Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci (2013) 1.32
Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging (2007) 1.26
The role of astroglia in neuroprotection. Dialogues Clin Neurosci (2009) 1.14
Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front Aging Neurosci (2014) 1.02
Glia maturation factor modulates beta-amyloid-induced glial activation, inflammatory cytokine/chemokine production and neuronal damage. Brain Res (2008) 1.01
Oligomeric amyloid β induces IL-1β processing via production of ROS: implication in Alzheimer's disease. Cell Death Dis (2013) 0.96
Biomarkers in Alzheimer's disease: past, present and future. Biomark Med (2010) 0.93
Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit. Antioxid Redox Signal (2014) 0.92
Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy. J Neuroinflammation (2006) 0.87
IPAF inflammasome is involved in interleukin-1β production from astrocytes, induced by palmitate; implications for Alzheimer's Disease. Neurobiol Aging (2013) 0.82
Interleukin-1β in Central Nervous System Injury and Repair. Eur J Neurodegener Dis (2012) 0.80
Are Anxiety Disorders Associated with Accelerated Aging? A Focus on Neuroprogression. Neural Plast (2015) 0.77
Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model. J Alzheimers Dis (2008) 0.77
Age-dependent differences in microglial responses to systemic inflammation are evident as early as middle age. Physiol Genomics (2016) 0.75
Assessment of neuroinflammation in a mouse model of obesity and β-amyloidosis using PET. J Neuroinflammation (2016) 0.75
Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement. Mol Neurobiol (2016) 0.75
Atorvastatin in improvement of cognitive impairments caused by amyloid β in mice: involvement of inflammatory reaction. BMC Neurol (2016) 0.75
Cytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimer's Disease. J Clin Cell Immunol (2016) 0.75
Screening for the protective effect target of deproteinized extract of calf blood and its mechanisms in mice with CCl4-induced acute liver injury. PLoS One (2017) 0.75
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A (1989) 5.97
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem (2002) 5.63
Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci (2000) 4.14
Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol (1998) 2.73
Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol (1991) 2.63
Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol (2000) 2.37
Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol (1995) 2.35
Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging (2001) 2.20
Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A (1996) 2.18
Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging (2001) 2.00
In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging (1997) 1.60
Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci (2003) 1.56
Glial-neuronal interactions in Alzheimer disease: progressive association of IL-1alpha+ microglia and S100beta+ astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol (1997) 1.51
Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock (2004) 1.36
Microglial interleukin-1 alpha expression in human head injury: correlations with neuronal and neuritic beta-amyloid precursor protein expression. Neurosci Lett (1994) 1.32
Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. Neuron (1995) 1.28
Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo. Neurobiol Aging (2004) 1.18
Interleukin-1 and the interleukin-1 type 1 receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury. J Cereb Blood Flow Metab (2005) 1.17
Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution. Neuropathol Appl Neurobiol (1995) 1.13
The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease. Neurobiol Aging (2001) 1.11
Activation of nuclear factor-kappaB signaling pathway by interleukin-1 after hypoxia/ischemia in neonatal rat hippocampus and cortex. J Neurochem (2005) 1.03
Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. J Mol Neurosci (2004) 1.02
Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits. Neurobiol Aging (1996) 1.00
Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model. Curr Alzheimer Res (2005) 0.95
Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound. J Med Chem (2002) 0.92
Brain-IL-1 beta triggers astrogliosis through induction of IL-6: inhibition by propranolol and IL-10. Med Sci Monit (2004) 0.90
Relevance of protein nitration in brain injury: a key pathophysiological mechanism in neurodegenerative, autoimmune, or inflammatory CNS diseases and stroke. Amino Acids (2003) 0.85
The role of chronic self-propagating glial responses in neurodegeneration: implications for long-lived survivors of human immunodeficiency virus. J Neurovirol (1997) 0.83
Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest (2005) 3.15
Hippocampal sclerosis in advanced age: clinical and pathological features. Brain (2011) 2.16
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation (2007) 1.70
Protein kinase involved in lung injury susceptibility: evidence from enzyme isoform genetic knockout and in vivo inhibitor treatment. Proc Natl Acad Sci U S A (2003) 1.62
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J Neuroinflammation (2008) 1.57
Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. Brain Res (2009) 1.53
Effect of stimulation and antagonism of interleukin-1 signaling on preterm delivery in mice. J Soc Gynecol Investig (2005) 1.53
University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology. Curr Alzheimer Res (2012) 1.52
Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. Bioorg Med Chem (2009) 1.49
Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov (2009) 1.45
Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging (2004) 1.42
Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol (2013) 1.41
Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci (2006) 1.39
Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis (2005) 1.39
Bacterially-induced preterm labor and regulation of prostaglandin-metabolizing enzyme expression in mice: the role of toll-like receptor 4. Biol Reprod (2003) 1.35
Glial activation links early-life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of proinflammatory cytokine upregulation. Epilepsia (2007) 1.32
Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis. Neurosci Res (2007) 1.27
Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci (2012) 1.27
Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci U S A (2002) 1.26
Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ). J Neuroinflammation (2011) 1.25
A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. J Mol Neurosci (2004) 1.24
Intrauterine infection and preterm labor. Semin Fetal Neonatal Med (2011) 1.22
Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia (2006) 1.22
MFG-E8 regulates microglial phagocytosis of apoptotic neurons. J Neuroimmune Pharmacol (2008) 1.20
Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38. Glia (2004) 1.19
Non-muscle myosin light chain kinase isoform is a viable molecular target in acute inflammatory lung injury. Am J Respir Cell Mol Biol (2010) 1.19
Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo. Neurobiol Aging (2004) 1.18
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett (2006) 1.18
Activation of toll-like receptors 2 or 3 and preterm delivery in the mouse. Reprod Sci (2007) 1.17
Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets (2005) 1.16
S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J Neurochem (2005) 1.13
Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain (2013) 1.13
An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury. Bioorg Med Chem Lett (2003) 1.11
ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci (2004) 1.10
The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS. Aging Dis (2010) 1.09
The p38α MAPK regulates microglial responsiveness to diffuse traumatic brain injury. J Neurosci (2013) 1.08
Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem (2013) 1.07
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J Neuroinflammation (2008) 1.07
Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol (2010) 1.06
A role for long chain myosin light chain kinase (MLCK-210) in microvascular hyperpermeability during severe burns. Shock (2007) 1.05
Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. J Alzheimers Dis (2011) 1.03
Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα. Mol Neurodegener (2011) 1.03
Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. J Mol Neurosci (2004) 1.02
Enhanced microglial activation and proinflammatory cytokine upregulation are linked to increased susceptibility to seizures and neurologic injury in a 'two-hit' seizure model. Brain Res (2009) 1.01
Mild cognitive impairment: statistical models of transition using longitudinal clinical data. Int J Alzheimers Dis (2012) 1.01
A calmodulin-regulated protein kinase linked to neuron survival is a substrate for the calmodulin-regulated death-associated protein kinase. Biochemistry (2004) 1.00
Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. Bioorg Med Chem (2010) 0.99
Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging (2011) 0.99
The adaptor protein MyD88 is essential for E coli-induced preterm delivery in mice. Am J Obstet Gynecol (2009) 0.98
Synergy between viral and bacterial toll-like receptors leads to amplification of inflammatory responses and preterm labor in the mouse. Biol Reprod (2010) 0.98
Minozac treatment prevents increased seizure susceptibility in a mouse "two-hit" model of closed skull traumatic brain injury and electroconvulsive shock-induced seizures. J Neurotrauma (2010) 0.98
Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLoS One (2013) 0.97
Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia. J Alzheimers Dis (2013) 0.97
Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS One (2013) 0.96
APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. J Neurochem (2015) 0.96
DAPK catalytic activity in the hippocampus increases during the recovery phase in an animal model of brain hypoxic-ischemic injury. Biochim Biophys Acta (2002) 0.96
MLCK210 gene knockout or kinase inhibition preserves lung function following endotoxin-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol (2007) 0.96
Cervical varix accompanied by placenta previa in twin pregnancy. J Obstet Gynaecol Res (2004) 0.95
Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model. Curr Alzheimer Res (2005) 0.95
Surfactant protein (SP)-A suppresses preterm delivery and inflammation via TLR2. PLoS One (2013) 0.94
Regulation of apoptosis and innate immune stimuli in inflammation-induced preterm labor. J Immunol (2013) 0.93
Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol Neurodegener (2014) 0.93
Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound. J Med Chem (2002) 0.92
Increased susceptibility of S100B transgenic mice to perinatal hypoxia-ischemia. Ann Neurol (2004) 0.92
Myosin light chain kinase (210 kDa) is a potential cytoskeleton integrator through its unique N-terminal domain. Exp Cell Res (2004) 0.92
Cognitive impairment in humanized APP×PS1 mice is linked to Aβ(1-42) and NOX activation. Neurobiol Dis (2011) 0.91
A Step-up Approach for Cell Therapy in Stroke: Translational Hurdles of Bone Marrow-Derived Stem Cells. Transl Stroke Res (2011) 0.91
Nonmuscle myosin light chain kinase regulates murine asthmatic inflammation. Am J Respir Cell Mol Biol (2014) 0.91
Death-associated protein kinase phosphorylates mammalian ribosomal protein S6 and reduces protein synthesis. Biochemistry (2006) 0.90
Death-associated protein kinase as a potential therapeutic target. Expert Opin Ther Targets (2002) 0.90
"End-stage" neurofibrillary tangle pathology in preclinical Alzheimer's disease: fact or fiction? J Alzheimers Dis (2011) 0.90
Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. Alzheimers Dement (2013) 0.89
Mechanism of interleukin-1β induced-increase in mouse intestinal permeability in vivo. J Interferon Cytokine Res (2012) 0.89
Deletion of MLCK210 induces subtle changes in vascular reactivity but does not affect cardiac function. Am J Physiol Heart Circ Physiol (2005) 0.88
De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders. Curr Alzheimer Res (2006) 0.88
Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug. J Neuroimmunol (2008) 0.88